What is Pmv Pharmaceuticals, Inc.'s earnings per share (EPS)?

Pmv Pharmaceuticals, Inc. (PMVP) reported diluted earnings per share of $-1.48 for fiscal year 2025. This represents a -29.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pmv Pharmaceuticals, Inc. Financials

PMVP

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Pmv Pharmaceuticals, Inc. (PMVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMVP FY2025 2026-05-12

PMV’s cash reserve is being converted into research spending in an asset-light model with little balance-sheet leverage.

Cash slipped only modestly from the prior year, ending at $38.0M, but that stability is misleading because operating cash outflow widened to -$73.6M. The offset came from a positive investing inflow of $70.2M, so liquidity was supported by converting balance-sheet resources rather than by the business producing cash.

These are cash-real losses: net loss of -$77.7M was almost identical to operating cash burn, while capital spending was just $29K. That combination says the business is not consuming cash to build factories or equipment; it is consuming cash mainly to fund ongoing research and operations.

The company remains equity-financed, not debt-funded: total liabilities were only $11.9M versus equity of $104.7M. Management also protected the research program; R&D kept rising while SG&A fell, so spending is becoming more concentrated on development rather than on corporate overhead.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Pmv Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Pmv Pharmaceuticals, Inc. carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.09, Pmv Pharmaceuticals, Inc. holds $10.09 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Pmv Pharmaceuticals, Inc. generates a -74.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -33.5% the prior year.

Piotroski F-Score Weak

1/9

Pmv Pharmaceuticals, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.95x

For every $1 of reported earnings, Pmv Pharmaceuticals, Inc. generates $0.95 in operating cash flow (-$73.6M OCF vs -$77.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-13.6x

Pmv Pharmaceuticals, Inc. earns $-13.6 in operating income for every $1 of interest expense (-$86.2M vs $6.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$86.1M

YoY-2.1%

Pmv Pharmaceuticals, Inc.'s EBITDA was -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.1% from the prior year.

Net Income

-$77.7M

YoY-32.0%

Pmv Pharmaceuticals, Inc. reported -$77.7M in net income in fiscal year 2025. This represents a decrease of 32.0% from the prior year.

EPS (Diluted)

$-1.48

YoY-29.8%

Pmv Pharmaceuticals, Inc. earned $-1.48 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 29.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$73.6M

YoY-41.7%

Pmv Pharmaceuticals, Inc. generated -$73.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 41.7% from the prior year.

Cash & Debt

$38.0M

YoY-7.1%

5Y CAGR-36.3%

Pmv Pharmaceuticals, Inc. held $38.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

53M

YoY+2.7%

5Y CAGR+3.6%

Pmv Pharmaceuticals, Inc. had 53M shares outstanding in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-74.2%

YoY-40.8pp

5Y CAGR-64.6pp

Pmv Pharmaceuticals, Inc.'s ROE was -74.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 40.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$69.9M

YoY+19.4%

5Y CAGR+23.9%

Pmv Pharmaceuticals, Inc. invested $69.9M in research and development in fiscal year 2025. This represents an increase of 19.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$29K

YoY-95.6%

5Y CAGR-27.8%

Pmv Pharmaceuticals, Inc. invested $29K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.6% from the prior year.

PMVP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$69.9M+19.4%	$58.5M+4.7%	$55.9M+7.5%	$52.0M+42.5%	$36.5M+52.5%	$23.9M
SG&A Expenses	$16.3M-39.3%	$26.9M+11.0%	$24.2M-3.2%	$25.1M+14.9%	$21.8M+98.0%	$11.0M
Operating Income	-$86.2M-0.9%	-$85.4M-6.6%	-$80.1M-4.0%	-$77.0M-32.2%	-$58.3M-66.8%	-$34.9M
Interest Expense	$6.3M-40.5%	$10.7M-4.6%	$11.2M+208.0%	$3.6M+707.8%	$449K-31.0%	$651K
Income Tax	-$2.2M+86.5%	-$16.1M-805100.0%	$2K+122.2%	-$9K-139.1%	$23K+283.3%	$6K
Net Income	-$77.7M-32.0%	-$58.9M+14.6%	-$69.0M+5.9%	-$73.3M-26.7%	-$57.8M-68.0%	-$34.4M
EPS (Diluted)	$-1.48-29.8%	$-1.14+20.8%	$-1.44+10.6%	$-1.61-25.8%	$-1.28+46.7%	$-2.40

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$15.3M	N/A	$18.2M-1.0%	$18.4M+5.5%	$17.4M	N/A	$16.9M+15.9%	$14.6M
SG&A Expenses	$3.7M	N/A	$4.3M-3.7%	$4.5M+8.6%	$4.1M	N/A	$4.9M-10.8%	$5.5M
Operating Income	-$19.0M	N/A	-$22.5M+1.6%	-$22.9M-6.1%	-$21.6M	N/A	-$21.9M-8.5%	-$20.2M
Interest Expense	$980K	N/A	$1.5M-12.4%	$1.7M-12.7%	$1.9M	N/A	$2.6M-6.6%	$2.8M
Income Tax	-$2.2M	N/A	-$6K-220.0%	$5K+100.2%	-$2.2M	N/A	$74K+100.5%	-$16.2M
Net Income	-$18.0M	N/A	-$21.1M+0.7%	-$21.2M-21.6%	-$17.4M	N/A	-$19.2M-1485.0%	-$1.2M
EPS (Diluted)	$-0.34	N/A	$-0.40+2.4%	$-0.41-20.6%	$-0.34	N/A	$-0.37-1750.0%	$-0.02

PMVP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$116.6M-39.1%	$191.3M-24.1%	$252.2M-6.7%	$270.3M-18.5%	$331.6M-9.3%	$365.5M
Current Assets	$115.2M-34.4%	$175.7M-15.3%	$207.4M-16.0%	$247.0M-18.0%	$301.3M-17.4%	$364.8M
Cash & Equivalents	$38.0M-7.1%	$40.9M+8.4%	$37.7M-65.2%	$108.3M-37.2%	$172.5M-52.3%	$361.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.8M-22.1%	$15.2M-42.5%	$26.5M+9.0%	$24.3M+5.5%	$23.0M+259.0%	$6.4M
Current Liabilities	$11.4M-20.6%	$14.4M+2.4%	$14.0M+29.5%	$10.8M-11.4%	$12.2M+90.6%	$6.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$104.7M-40.5%	$176.1M-22.0%	$225.7M-8.3%	$246.0M-20.3%	$308.6M-14.1%	$359.1M
Retained Earnings	-$446.5M-21.1%	-$368.7M-18.9%	-$310.0M-28.6%	-$241.0M-43.7%	-$167.7M-52.6%	-$109.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$96.6M-17.2%	$116.6M-12.9%	$133.8M-12.4%	$152.9M-10.4%	$170.6M-10.8%	$191.3M-14.4%	$223.5M-5.9%	$237.5M
Current Assets	$95.8M-16.9%	$115.2M-13.0%	$132.4M-8.9%	$145.3M-11.1%	$163.5M-6.9%	$175.7M-7.4%	$189.6M-13.3%	$218.8M
Cash & Equivalents	$39.1M+3.0%	$38.0M+4.5%	$36.3M-17.7%	$44.1M-14.1%	$51.3M+25.6%	$40.9M-16.3%	$48.8M+0.6%	$48.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.6M-27.5%	$11.8M-7.7%	$12.8M+4.9%	$12.3M+16.7%	$10.5M-31.0%	$15.2M-40.6%	$25.6M+10.2%	$23.2M
Current Liabilities	$8.6M-24.7%	$11.4M-7.2%	$12.3M+6.0%	$11.6M+18.9%	$9.8M-32.1%	$14.4M+6.0%	$13.6M+19.1%	$11.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$88.0M-16.0%	$104.7M-13.5%	$121.0M-13.9%	$140.6M-12.2%	$160.1M-9.1%	$176.1M-11.0%	$197.9M-7.7%	$214.3M
Retained Earnings	-$464.5M-4.0%	-$446.5M-4.2%	-$428.4M-5.2%	-$407.4M-5.5%	-$386.1M-4.7%	-$368.7M-6.7%	-$345.7M-5.9%	-$326.5M

PMVP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$73.6M-43.5%	-$51.3M+7.9%	-$55.7M+12.7%	-$63.8M-36.9%	-$46.6M-42.2%	-$32.7M
Capital Expenditures	$29K-95.6%	$655K-31.9%	$962K-88.0%	$8.0M+491.8%	$1.3M+811.5%	$148K
Free Cash Flow	-$73.6M-41.7%	-$51.9M+8.3%	-$56.6M+21.1%	-$71.7M-49.7%	-$47.9M-45.7%	-$32.9M
Investing Cash Flow	$70.2M+31.5%	$53.4M+205.6%	-$50.5M-3594.8%	-$1.4M+99.0%	-$143.6M-614.4%	$27.9M
Financing Cash Flow	$505K+61.3%	$313K-99.1%	$35.6M+3613.7%	$958K-52.6%	$2.0M-99.3%	$293.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$19.7M-14.5%	-$17.2M+13.3%	-$19.8M-8.3%	-$18.3M-0.2%	-$18.3M-9.6%	-$16.7M+1.1%	-$16.8M-953.8%	-$1.6M
Capital Expenditures	$0-100.0%	$15K+1600.0%	-$1K-109.1%	$11K+175.0%	$4K-92.9%	$56K+5500.0%	$1K-75.0%	$4K
Free Cash Flow	-$19.7M-14.4%	-$17.2M+13.2%	-$19.8M-8.2%	-$18.3M-0.2%	-$18.3M-9.3%	-$16.7M+0.7%	-$16.8M-951.2%	-$1.6M
Investing Cash Flow	$20.8M+12.9%	$18.4M+53.3%	$12.0M+9.5%	$11.0M-61.7%	$28.7M+270.8%	$7.7M-54.8%	$17.1M+636.9%	$2.3M
Financing Cash Flow	$0-100.0%	$392K	$0-100.0%	$103K+930.0%	$10K-94.2%	$172K	$0-100.0%	$141K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PMVP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-74.2%-40.8pp	-33.5%-2.9pp	-30.6%-0.8pp	-29.8%-11.0pp	-18.8%-9.2pp	-9.6%
Return on Assets	-66.7%-35.9pp	-30.8%-3.4pp	-27.4%-0.2pp	-27.1%-9.7pp	-17.4%-8.0pp	-9.4%
Current Ratio	10.09-2.1	12.22-2.6	14.78-8.0	22.80-1.9	24.66-32.2	56.91
Debt-to-Equity	0.11+0.0	0.09-0.0	0.12+0.0	0.10+0.0	0.07+0.1	0.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-20.5%	N/A	-17.4%-2.3pp	-15.1%-4.2pp	-10.9%	N/A	-9.7%-9.1pp	-0.6%
Return on Assets	-18.7%	N/A	-15.7%-1.8pp	-13.9%-3.7pp	-10.2%	N/A	-8.6%-8.1pp	-0.5%
Current Ratio	11.14+1.0	10.09-0.7	10.76-1.8	12.52-4.2	16.75+4.5	12.22-1.8	13.98-5.2	19.22
Debt-to-Equity	0.10-0.0	0.110.0	0.11+0.0	0.09+0.0	0.07-0.0	0.09-0.0	0.13+0.0	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Prelude Therapeutics Inc PRLD

$356.8M

Adlai Nortye Ltd. ANL

$870.0M

Mink Therapeutics, Inc. INKT

$53.4M

Applied Therapeutics APLT

$14.9M

Celularity Inc CELU

$23.4M

Frequently Asked Questions

Is Pmv Pharmaceuticals, Inc. profitable?

No, Pmv Pharmaceuticals, Inc. (PMVP) reported a net income of -$77.7M in fiscal year 2025.

What is Pmv Pharmaceuticals, Inc.'s EBITDA?

Pmv Pharmaceuticals, Inc. (PMVP) had EBITDA of -$86.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pmv Pharmaceuticals, Inc.'s return on equity (ROE)?

Pmv Pharmaceuticals, Inc. (PMVP) has a return on equity of -74.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pmv Pharmaceuticals, Inc.'s free cash flow?

Pmv Pharmaceuticals, Inc. (PMVP) generated -$73.6M in free cash flow during fiscal year 2025. This represents a -41.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pmv Pharmaceuticals, Inc.'s operating cash flow?

Pmv Pharmaceuticals, Inc. (PMVP) generated -$73.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pmv Pharmaceuticals, Inc.'s total assets?

Pmv Pharmaceuticals, Inc. (PMVP) had $116.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pmv Pharmaceuticals, Inc.'s capital expenditures?

Pmv Pharmaceuticals, Inc. (PMVP) invested $29K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pmv Pharmaceuticals, Inc. spend on research and development?

Pmv Pharmaceuticals, Inc. (PMVP) invested $69.9M in research and development during fiscal year 2025.

How many shares does Pmv Pharmaceuticals, Inc. have outstanding?

Pmv Pharmaceuticals, Inc. (PMVP) had 53M shares outstanding as of fiscal year 2025.

What is Pmv Pharmaceuticals, Inc.'s current ratio?

Pmv Pharmaceuticals, Inc. (PMVP) had a current ratio of 10.09 as of fiscal year 2025, which is generally considered healthy.

What is Pmv Pharmaceuticals, Inc.'s debt-to-equity ratio?

Pmv Pharmaceuticals, Inc. (PMVP) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pmv Pharmaceuticals, Inc.'s return on assets (ROA)?

Pmv Pharmaceuticals, Inc. (PMVP) had a return on assets of -66.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pmv Pharmaceuticals, Inc.'s cash runway?

Based on fiscal year 2025 data, Pmv Pharmaceuticals, Inc. (PMVP) had $38.0M in cash against an annual operating cash burn of $73.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pmv Pharmaceuticals, Inc.'s Piotroski F-Score?

Pmv Pharmaceuticals, Inc. (PMVP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pmv Pharmaceuticals, Inc.'s earnings high quality?

Pmv Pharmaceuticals, Inc. (PMVP) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pmv Pharmaceuticals, Inc. cover its interest payments?

Pmv Pharmaceuticals, Inc. (PMVP) has an interest coverage ratio of -13.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pmv Pharmaceuticals, Inc.?

Pmv Pharmaceuticals, Inc. (PMVP) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.